Clebopride

• Description:

  Clebopride is an orally active dopamine Receptor antagonist. Clebopride acts on dopamine D2 receptors and has antiemetic and prokinetic effects. Clebopride can be used in the study of functional gastrointestinal disorders[1][2][3][4].

• UNSPSC:

  12352005

• Hazard Statement:

  H302

• Target:

  Adrenergic Receptor; Dopamine Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein; Neuronal Signaling

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/clebopride.html

• Smiles:

  O=C(NC1CCN(CC2=CC=CC=C2)CC1)C3=CC(Cl)=C(N)C=C3OC

• Molecular Formula:

  C20H24ClN3O2

• Molecular Weight:

  373.88

• Precautions:

  P264-P270-P330-P501

• References & Citations:

  [1]Reis-Carneiro D, et al. Clebopride-Associated Movement Disorders. Mov Disord Clin Pract. 2023 Sep 6;10 (10) :1562-1563.|[2]Elliott PN, et al. Substituted benzamides as cerebral dopamine antagonists in rodents. Neuropharmacology. 1977 May;16 (5) :333-42.|[3]Segura J, et al. The pharmacokinetics of a new benzamide drug clebopride, in the rat and the dog. J Pharm Pharmacol. 1981 Apr;33 (4) :214-8.|[4]Takeda K, et al. Clebopride enhances contractility of the guinea pig stomach by blocking peripheral D2 dopamine receptor and alpha-2 adrenoceptor. J Pharmacol Exp Ther. 1991 May;257 (2) :806-11.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• CAS Number:

  [55905-53-8]